Pharma Journalist -

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with…
Read More...

Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced the acquisition of Nalpropion Pharmaceuticals. As a result of…
Read More...

Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the…
Read More...

Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been…
Read More...

SMi Reports: Interview excerpt with Bionical EMAS’ Executive VP, Tom Watson released for SMi’s 9th Annual Conference on Orphan Drugs & Rare Diseases, in London in less than 3 weeks…
Read More...

SMI Reports: Overview of networking opportunities and key features to expect from the upcoming HPAPI USA conference 2019, in Boston With is less than 4 weeks until the 2019 HPAPI USA…
Read More...

SMi Group Reports: CEO of twoXAR to present at SMi’s Ophthalmic Drugs conference commencing on 18th- 20th November 2019, in London The Ophthalmic Drugs conference is taking place on…
Read More...

Moderna, Inc., a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,…
Read More...

SpringWorks Therapeutics announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the…
Read More...

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready…
Read More...